Home > Riviste > Minerva Medica > Fascicoli precedenti > Minerva Medica 2020 October;111(5) > Minerva Medica 2020 October;111(5):395-410

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

REVIEW  ACUTE LEUKEMIAS IN 2020: STATE OF THE ART Freefree

Minerva Medica 2020 October;111(5):395-410

DOI: 10.23736/S0026-4806.20.07019-6

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future

Michele GOTTARDI 1, Alessandra SPEROTTO 2, Andrea GHELLI LUSERNA DI RORÀ 3, Antonella PADELLA 3, Delia CANGINI 4, Maria B. GIANNINI 4, Giorgia SIMONETTI 3 , Giovanni MARTINELLI 5, Claudio CERCHIONE 4

1 IRCCS Istituto Oncologico Veneto (IOV), Padua, Italy; 2 Unit of Hematology and Transplant, Dipartimento di Area Medica (DAME), University Hospital of Udine, Udine, Italy; 3 Biosciences Laboratory, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Forlì-Cesena, Italy; 4 Unit of Hematology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Forlì-Cesena, Italy; 5 IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Forlì-Cesena, Italy



After being in the therapeutic wilderness for several decades, acute myeloid leukemia has been recently thrust into the limelight with a series of drug approvals. Technical refinements in production, genetic manipulation and chemical modification of monoclonal antibodies led to growing interest in antibodies-based treatment strategies. Much of the focus of these efforts in acute myeloid leukemia has been on CD33 as a target. On September 2, 2017, the U.S. Food and Drug Administration approved gemtuzumab ozogamicin for treatment of relapsed or refractory CD33+ acute myeloid leukemia. This signals a new chapter in the long and unusual story of gemtuzumab ozogamicin, which was the first antibody-drug conjugate approved for human use by the Food and Drug Administration. In this review we have analyzed the history of this drug which, among several mishaps, is experiencing a second youth and still represents a field to be further explored.


KEY WORDS: Leukemia, myeloid, acute; Gemtuzumab; Clinical Trials as topic; Biomarkers

inizio pagina